Log In
BCIQ
Print this Print this
 

Volixibat (SHP626) (formerly LUM002)

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionOral inhibitor of solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2; ASBT; IBAT)
Molecular Target Solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2) (ASBT) (IBAT)
Mechanism of ActionNa channel blocker
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationNon-alcoholic steatohepatitis (NASH)
Indication DetailsTreat non-alcoholic steatohepatitis (NASH) with liver fibrosis
Regulatory Designation U.S. - Fast Track (Treat non-alcoholic steatohepatitis (NASH) with liver fibrosis)
PartnerShire plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$565.3M

$300.3M

$265.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/11/2014

$565.3M

$300.3M

$265.0M

Get a free BioCentury trial today